Xiangyu MedicalLtd Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Yongzheng He

Geschäftsführender

CN¥806.4k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	6.2yrs
Eigentum des Geschäftsführers	5.9%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.5yrs

Jüngste Management Updates

Recent updates

Why Xiangyu MedicalLtd's (SHSE:688626) Soft Earnings Are Just The Beginning Of Its Problems

Nov 06

Further Upside For Xiangyu Medical Co.,Ltd (SHSE:688626) Shares Could Introduce Price Risks After 41% Bounce

Oct 09

Xiangyu Medical Co.,Ltd (SHSE:688626) Looks Inexpensive But Perhaps Not Attractive Enough

Aug 24

Xiangyu MedicalLtd (SHSE:688626) Seems To Use Debt Quite Sensibly

Jul 04

Xiangyu MedicalLtd's (SHSE:688626) Performance Raises Some Questions

Apr 24

CN¥50.78: That's What Analysts Think Xiangyu Medical Co.,Ltd (SHSE:688626) Is Worth After Its Latest Results

Apr 21

Capital Allocation Trends At Xiangyu MedicalLtd (SHSE:688626) Aren't Ideal

Apr 18

Pinning Down Xiangyu Medical Co.,Ltd's (SHSE:688626) P/E Is Difficult Right Now

Mar 26

Geschäftsführer

Yongzheng He (52 yo)

6.2yrs

Amtszeit

CN¥806,400

Vergütung

Mr. Yongzheng He serves as Chairman of the Board, General Manager and Technical Director at Xiangyu Medical Co.,Ltd.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Yongzheng He	Chairman	6.2yrs	CN¥806.40k	5.93% CN¥ 277.9m
Junling Guo	Deputy GM	6.2yrs	CN¥602.40k	keine Daten
Zhong Ming Ye	Independent Director	2.9yrs	CN¥60.00k	keine Daten
Jue Wang	Independent Director	2.9yrs	CN¥60.00k	keine Daten
Zhifeng Li	Chairman of the Supervisory Board	no data	keine Daten	keine Daten
Xuebei Zhao	Employee Representative Supervisor	no data	keine Daten	keine Daten
Kai Yang	Employee Representative Supervisor	no data	keine Daten	keine Daten

4.5yrs

Durchschnittliche Betriebszugehörigkeit

51yo

Durchschnittliches Alter

Erfahrener Vorstand: 688626Die Vorstandsmitglieder gelten als erfahren (4.5 Jahre durchschnittliche Amtszeit).

Xiangyu MedicalLtd Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Xiangyu Medical Co.,Ltd, Annual General Meeting, May 15, 2024

Insufficient new directors

Insufficient new directors

Recent updates

New minor risk - Share price stability

Xiangyu Medical Co.,Ltd (SHSE:688626) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment improves as stock rises 24%

Why Xiangyu MedicalLtd's (SHSE:688626) Soft Earnings Are Just The Beginning Of Its Problems

Third quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.46 in 3Q 2023)

Investor sentiment deteriorates as stock falls 18%

Further Upside For Xiangyu Medical Co.,Ltd (SHSE:688626) Shares Could Introduce Price Risks After 41% Bounce

New minor risk - Share price stability

Xiangyu Medical Co.,Ltd to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 17%

Price target decreased by 16% to CN¥40.78

Second quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.44 in 2Q 2023)

Xiangyu Medical Co.,Ltd (SHSE:688626) Looks Inexpensive But Perhaps Not Attractive Enough

Xiangyu MedicalLtd (SHSE:688626) Seems To Use Debt Quite Sensibly

Xiangyu Medical Co.,Ltd to Report First Half, 2024 Results on Aug 30, 2024

Xiangyu MedicalLtd's (SHSE:688626) Performance Raises Some Questions

CN¥50.78: That's What Analysts Think Xiangyu Medical Co.,Ltd (SHSE:688626) Is Worth After Its Latest Results

Xiangyu Medical Co.,Ltd, Annual General Meeting, May 15, 2024

Capital Allocation Trends At Xiangyu MedicalLtd (SHSE:688626) Aren't Ideal

First quarter 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.24 in 1Q 2023)

Xiangyu Medical Co.,Ltd to Report Q1, 2024 Results on Apr 18, 2024

Pinning Down Xiangyu Medical Co.,Ltd's (SHSE:688626) P/E Is Difficult Right Now

Now 21% undervalued after recent price drop

Investor sentiment improves as stock rises 18%

Consensus EPS estimates fall by 15%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 15%

Third quarter 2023 earnings released: EPS: CN¥0.46 (vs CN¥0.33 in 3Q 2022)

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Xiangyu Medical Co.,Ltd (SHSE:688626) announces an Equity Buyback for CNY 160 million worth of its shares.

Second quarter 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.19 in 2Q 2022)

Xiangyu Medical Co.,Ltd to Report First Half, 2023 Results on Aug 07, 2023

First quarter 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.06 in 1Q 2022)

Investor sentiment improves as stock rises 17%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings released: EPS: CN¥0.33 (vs CN¥0.28 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.40 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Xiangyu Medical Co.,Ltd (SHSE:688626) announces an Equity Buyback for CNY 160 million worth of its shares.

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Insufficient new directors

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Geschäftsführer

Amtszeit

Vergütung

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter